Onxeo Announces That the Shareholders’ Meeting of May 29, 2020 Has Approved All Ordinary Resolutions

Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, announces that today’s Shareholders’ General Meeting approved all the ordinary resolutions, with over 87% of favourable votes.

The company's shareholders notably renewed the terms of office of Judith Greciet, Financière de la Montagne and Christine Garnier as directors for a further period of three years.

Onxeo would like to thank all of its shareholders for their commitment and support.

Given the constraints of the COVID-19 context, Onxeo's Annual General Meeting was held in camera and was webcast live on the Internet.

The quorum of 21.01% did not permit the resolutions to be discussed on an extraordinary basis and an Extraordinary General Meeting on the second call will be held on June 19, 2020 at 10 am (CEST), also in camera. The shareholders of the Company who have not cast their vote so far are thus invited to vote exclusively through mail or online voting prior to the General Meeting on the second call:

- online voting is available and must be used as a priority: the secure voting platforms VOTACCESS in France and Computershare in Denmark are reopened as of today;

- alternatively, shareholders can also vote by postal ballot, in accordance with the terms and conditions indicated in the prior notice published in the BALO on April 24, 2020.

The vote of shareholders who submitted their vote remotely at the first general meeting remains valid and counted for the general meeting on the second call

All documents relating to this General Meeting remain available on the company's website, in the General Meetings section. If you have any questions about voting procedures, please contact the Investor Relations team by e-mail at [e-mail].

***

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.